Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210

被引：35
|
作者：
Balar, Arjun Vasant
Dreicer, Robert
Loriot, Yohann
Perez-Gracia, Jose Luis
Hoffman-Censits, Jean H.
Petrylak, Daniel Peter
Van Der Heijden, Michiel Simon
Ding, Beiying
Shen, Xiaodong
Rosenberg, Jonathan E.
机构：
[1] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[2] Univ Virginia, Emily Couric Clin Canc Ctr, Charlottesville, VA USA
[3] Gustave Roussy, Villejuif, France
[4] Clin Univ Navarra, Pamplona, Spain
[5] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
[6] Yale Univ, Sch Med, New Haven, CT USA
[7] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[8] Netherlands Canc Inst, Dept Med Oncol, San Francisco, CA USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4523
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
    Necchi, A.
    Joseph, R. W.
    Loriot, Y.
    Hoffman-Censits, J.
    Perez Gracia, J. L.
    Petrylak, D. P.
    Zhu, Q.
    Ding, B.
    Kaiser, C.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
    Bellmunt, J.
    Balar, A.
    Galsky, M. D.
    Loriot, Y.
    Theodore, C.
    Grande Pulido, E.
    Castellano, D.
    Retz, M.
    Niegisch, G.
    Bracarda, S.
    Necchi, A.
    Vaishampayan, U.
    Sridhar, S.
    Eigl, B. J.
    Hussain, S.
    van der Heijden, M.
    Danner, B.
    Mariathasan, S.
    Legrand, F.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
    Balar, Arjun Vasant
    Galsky, Matt D.
    Loriot, Yohann
    Dawson, Nancy Ann
    Necchi, Andrea
    Srinivas, Sandy
    Joseph, Richard Wayne
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Drakaki, Alexandra
    Duran, Ignacio
    Rosenberg, Jonathan E.
    Powles, Thomas
    Hoffman-Censits, Jean H.
    Cui, Na
    Mariathasan, Sanjeev
    Thastrom, Ann Christine
    Abidoye, Oyewale O.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [4] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    von Amsberg, G.
    Balar, A. V.
    Dreicer, R.
    Loriot, Y.
    Perez-Gracia, J. L.
    Hoffman-Censits, J. H.
    Petrylak, D. P.
    van der Heijden, M. S.
    Shen, X.
    Ding, B.
    Rosenberg, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 106 - 106
  • [5] Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Shen, Xiaodong
    Ding, Beiying
    Ramirez-Montagut, Teresa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
    Necchi, A.
    Joseph, R. W.
    Loriot, Y.
    Hoffman-Censits, J.
    Perez-Gracia, J. L.
    Petrylak, D. P.
    Derleth, C. L.
    Tayama, D.
    Zhu, Q.
    Ding, B.
    Kaiser, C.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3044 - 3050
  • [7] Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).
    Dreicer, Robert
    Hoffman-Censits, Jean H.
    Flaig, Thomas W.
    Grande, Enrique
    Balmanoukian, Ani Sarkis
    von Amsberg, Gunhild
    Theodore, Christine
    Chowdhury, Simon
    Bracarda, Sergio
    Clement, Jessica Mary
    Yu, Evan Y.
    Kalebasty, Arash Rezazadeh
    Niegisch, Guenter
    Culine, Stephane
    Gordon, Michael S.
    Cui, Na
    Mariathasan, Sanjeev
    Legrand, Fatema A.
    Abidoye, Oyewale O.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
    Loriot, Y.
    Rosenberg, J. E.
    Powles, T. B.
    Necchi, A.
    Hussain, S.
    Morales, R.
    Retz, M.
    Niegisch, G.
    Duran, I.
    Theodore, C.
    Perez-Gracia, J. L.
    Grande Pulido, E.
    Thastrom, A.
    Danner, B.
    Mariathasan, S.
    Abidoye, O.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
    Hoffman-Censits, Jean H.
    Grivas, Petros
    Van der Heijden, Michiel Simon
    Dreicer, Robert
    Loriot, Yohann
    Retz, Margitta
    Vogelzang, Nicholas J.
    Perez-Gracia, Jose Luis
    Rezazadeh, Arash
    Bracarda, Sergio
    Yu, Evan Y.
    Hoimes, Christopher J.
    Bellmunt, Joaquim
    Quinn, David I.
    Petrylak, Daniel Peter
    Hussain, Syed A.
    Cui, Na
    Mariathasan, Sanjeev
    Abidoye, Oyewale O.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study.
    Bellmunt, Joaquim
    Pal, Sumanta K.
    Zheng, Hanzhe
    Tayama, Darren
    Chang, Dannis
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345